General Medical and Surgical Trials

Sponsor: Providence Medical Technology, Inc.

Principal Investigator: Rahul V. Shah, M.D.

Description: This study will evaluate the safety and effectiveness of a device called "Posterior Cervical Stabilization System” (PCSS) when used along with posterior cervical fusion (PCF) in combination with anterior cervical discectomy and fusion (ACDF) in the treatment of multi-level cervical degenerative disease.

NCT04229017

Phase III

Sponsor: Novartis Pharmaceuticals

Principal Investigator: M. Scott Dawson, M.D.

Description: This trial will study the effectiveness of implementing a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have increased LDL cholesterol, despite being treated with a statin drug.

NCT04873934

Sponsor: Adela, Inc.

Principal Investigator: Bac Nguyen, M.D.

Description: Case-control study to train and validate a genome-wide platform to detect multiple cancer types and to differentiate amongst cancer types.

NCT04873934

.

Sponsor: Delfi Diagnostics Inc.

Principal Investigator: Ekram Hanna, M.D.

Description: Blood test to train and test classifiers for lung cancer detection – blood draw prior to lung cancer screening radiology images obtained.

NCT04873934

Sponsor: Freenome

Principal Investigator: Mylene Go, M.D.

Description: Diagnostic study to assess the sensitivity and specificity of blood-based screening tests for the early detection of multiple cancers.

NCT04873934

Sponsor - AstraZeneca

Principal Investigator – Dr. Theodore Plush

Description - This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

Study Details | A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | ClinicalTrials.gov

Sponsor – Eli Lilly

Principal Investigator – Dr. Ekram Hanna

Description - The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).

Study Details | A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) | ClinicalTrials.gov

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) (lilly.com)

Sponsor – Freenome

Principal Investigator – Dr. Bac Nguyen (Mullica Hill)

Sub-Investigator – Dr. Nicole Zucconi (Vineland

Description - The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).

Study Details | Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening | ClinicalTrials.gov

Sponsor – New Amsterdam Pharma

Principal Investigator – Dr. Ekram Hanna

Description – This study is to evaluate the effect of Obicetrapib in participants with Atherosclerotic Cardiovascular Disease (ASCVD) who are not adequately controlled despite maximally tolerated lipid-lowering therapy to reduce the risk of cardiovascular death, myocardial infarction, stroke and non-elective coronary revascularization.

Study Record | Beta ClinicalTrials.gov

About the Study/Therapy | CVD Clinical Trial | PREVAIL (prevailcvot.com)

Sponsor – Novo Nordisk

Principal Investigator – Dr. M. Scott Dawson

Description - This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. Participants will get study medicine for once-monthly injections either in a pre-filled syringe to inject the study medicine into a skinfold or a pen-injector to inject the study medicine into flat skin. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.

Study Details | A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | ClinicalTrials.gov

Sponsor – Novartis Pharmaceuticals

Principal Investigator – Dr. Erev Tubb

Description – study to assess the efficacy and safety of two different doses of Ianalumab compared to placebo in adults with primary ITP (platelets count <30 G/L) who require first-line standard-of-care corticosteroids.

Study Record | Beta ClinicalTrials.gov

Sponsor – Novartis Pharmaceuticals

Principal Investigator – Dr. Erev Tubb

Description - The purpose of this study is to evaluate efficacy and safety of ianalumab compared to placebo in patients with warm autoimmune hemolytic anemia, who failed at least one line of treatment.

Study Record | Beta ClinicalTrials.gov

Sponsor – Pfizer

Principal Investigator – Dr. Ekram Hanna

Description - The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. 

Lyme Disease Study (valorlymestudy.com)

Study Record | Beta ClinicalTrials.gov

SeraTrials – A wide range of blood specimen collections studies for diagnoses that range from Chronic Kidney Disease, to cancer diagnosis and more. Please contact the office for more information.

Sponsor: Precision

Principal Investigator: Joseph Fanelle, M.D.

Description: Lab draw and/or saliva collection from patients with Prostate Cancer.